R&D LNPs: The unknown enabler behind mRNA vaccines Drug delivery technologies are crucial to allow drugs to reach their full potential, and yet they rarely receive much spotlight.
News Moderna’s flu vaccine trial delayed by case numbers Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st
News Moderna picks Oxfordshire for UK facility Moderna selects Harwell in Oxfordshire for its new UK facility, next door to the UKHSA.
Oncology Could cancer be the next mRNA breakthrough? mRNA vaccines achieved their first success against COVID-19, but could a cancer target be next?
R&D Partner Content mRNA Process Development & Manufacturing Summit Europe Event mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus.
News Vaxxas announces CEPI partnership to advance needle-free mRN... Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidem
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
